Anthea (on behalf of Dennis Ding)'s questions to Arbutus Biopharma Corp (ABUS) leadership • Q3 2024
Question
Anthea, on behalf of Dennis Ding, inquired about the expectations for functional cure data from the IM-PROVE I trial, specifically asking if the 20% functional cure target for Cohort A2 would be an incremental benefit on top of its baseline performance without continuous imdusiran.
Answer
Interim President and CEO Mike McElhaugh clarified that the 20% functional cure rate is an aspirational goal for the entire program, not an incremental target. Chief Medical Officer Dr. Karen Sims further corrected the premise of the question, explaining that all cohorts, including A2, received an initial imdusiran lead-in, with the key difference being the continuation of imdusiran during the interferon treatment phase in Cohort A1.